SAG1 protein mutant as well as preparation method and application thereof

By mutating N glycosylated amino acid sites in the yeast expression system, the non-glycosylated expression of SAG1 protein was improved, and the structural inhomogeneity and false positive problems caused by glycosylation in the yeast expression system were solved, and efficient purification was achieved and high yields of SAG1 protein reduce the cost and difficulty of testing and vaccine development.

CN118909070APending Publication Date: 2024-11-08ZHENGZHOU IMMUNO BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411114526.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The SAG1 protein obtained in the yeast expression system obtained in the prior art has uneven structure of the secreted protein due to glycosylation modification, resulting in high false positive rate in Toxoplasma gondii detection, and the purification process is difficult, costly, and non-glycosylated expression. Protein accounts for only about 28%, affecting the efficiency of diagnosis and vaccine development.

Method used

By directed mutation of N glycosylated amino acid sites, the non-glycosylated expression of SAG1 protein is increased, so that it reaches 100% in yeast cells, and purified by hollow fiber filtration and ConA column to reduce purification difficulty and improve yield .

Benefits of technology

It realizes efficient non-glycosylated expression and secretion of SAG1 protein, reduces the difficulty of purification process, improves the purity and yield of antigens, reduces costs, and enhances the efficiency of Toxoplasma gondii detection and vaccine development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004993247880000081
    Figure BDA0004993247880000081
  • Figure BDA0004993247880000082
    Figure BDA0004993247880000082
  • Figure BDA0004993247880000083
    Figure BDA0004993247880000083
Patent Text Reader

Abstract

The invention relates to the technical field of protein, in particular to an SAG1 protein mutant as well as a preparation method and application thereof. The invention provides an SAG1 protein mutant and a preparation method thereof, and an application of the SAG1 protein mutant in preparation of an IgM (Immunoglobulin M) detection kit, an IgG (Immunoglobulin G) detection kit or a toxoplasma gondii vaccine. According to the method, the expression quantity of the non-glycosylated SAG1 protein is increased from 28% to 100% by directionally mutating the N glycosylated amino acid, the yield of the SAG1 can be increased and the cost can be reduced without influencing the structure and function of the SAG1, the SAG1 protein can be secreted into a supernatant, the difficulty of a purification and separation process is reduced, and the yield is increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of protein technology, and in particular to a SAG1 protein mutant and a preparation method and application thereof. Background Art

[0002] Toxoplasma infection is common in the human population, regardless of gender or age. About 2 billion people are infected with Toxoplasma gondii worldwide. Czech physician Janku first reported human Toxoplasma infection in 1923, and Wolf first reported a case of congenital toxoplasmosis in 1939.

[0003] SAG1 protein is a specific antigen of the tachyzoite stage of Toxoplasma gondii. Although this protein only accounts for 3-5% of the total tachyzoite protein, after the body is infected with Toxoplasma gondii, most of the antibodies it produces are directed against SAG1 protein. SAG1 is important for the invasion of the parasite into host cells and its virulence, and has high immunogenicity and immune protection. In most Toxoplasma strains, SAG1 is relatively conservative and rarely mutates. Therefore, in the current field of Toxoplasma detection, SAG1 is widely used in the development of Toxoplasma vaccines and molecular diagnosis and ELISA detection of Toxoplasma infection.

[0004] Burg et al. cloned the SAG1 gene, which is about 1.1 kb long and has a protein size of about 30 kDa. Analysis showed that the transcription of the SAG1 protein starts from the second methionine codon, not the first. Due to its good immunogenicity, it has been used by many scholars in the research and development of diagnosis and vaccines.

[0005] As the main antigen protein for the body to recognize Toxoplasma gondii, SAG1 protein is a highly conformation-dependent protein, and the formation of its spatial structure mainly depends on the correct connection of disulfide bonds. Prokaryotic expression systems (such as Escherichia coli) lack the function of post-translational modification of proteins. Therefore, most recombinant SAG 1 proteins obtained in Escherichia coli in the past form inclusion bodies. The expression products do not have specific immune reactivity due to misfolding, and require complex denaturation and renaturation processes to restore partial activity. Therefore, most of them use eukaryotic expression systems to express SAG1. The yeast expression system has low expression cost, so it is commonly used as an expression system for in vitro diagnostic reagents. However, due to its overexpression of glycosylated proteins, the secreted protein structure is not uniform, and the verified glycosylated modified antigens are prone to false positives. Since the non-glycosylated expressed protein accounts for only about 28%, the advantage of yeast expression is reduced, the cost is high, and the purification process cannot guarantee that the SAG1 antigen with uniform structure can be obtained. Summary of the invention

[0006] In view of this, the present invention provides a SAG1 protein mutant and a preparation method and application thereof. The present invention provides a SAG1 protein mutant and a preparation method thereof, as well as an application of the SAG1 protein mutant in the preparation of an Ig M detection kit, an IgG detection kit or a Toxoplasma vaccine. The present invention increases the expression of non-glycosylated SAG1 protein in yeast cells from 28% to 100% by directed mutation of N-glycosylated amino acids, which can increase the yield of SAG1 and reduce the cost without affecting the structure and function of SAG1, and allows the SAG1 protein to be secreted into the supernatant, thereby reducing the difficulty of the purification and separation process and improving the yield.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides application of N212Q site mutation in increasing the non-glycosylated expression amount of SAG1 protein.

[0009] The present invention also provides a SAG1 protein mutant, including an N212Q site mutation.

[0010] In some specific embodiments of the present invention, the SAG1 protein mutant has:

[0011] (I), the amino acid sequence shown in SEQ ID NO: 1; or

[0012] (II) a sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence as shown in (I); or

[0013] (III) A sequence having a homology of 85% or more to the amino acid sequence shown in (I) or (II).

[0014] In some specific embodiments of the present invention, the sequences with a homology of more than 85% include sequences with a homology of more than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0015] In some specific embodiments of the present invention, the C-terminus or N-terminus of the SAG1 protein mutant is fused with a HIS tag or a flag tag.

[0016] The present invention also provides a nucleic acid molecule encoding the SAG1 protein mutant.

[0017] The present invention also provides a recombinant vector, comprising the nucleic acid molecule.

[0018] In some specific embodiments of the present invention, the recombinant vector comprises pPICK.

[0019] The present invention also provides a host, comprising the recombinant vector.

[0020] In some specific embodiments of the present invention, the host comprises yeast. Preferably, the yeast is Pichia pastoris GS115.

[0021] The present invention also provides the use of any of the following items in preparing a SAG1 protein mutant:

[0022] (I), the nucleic acid molecule; and / or

[0023] (II), the recombinant vector; and / or

[0024] (III) the host.

[0025] The present invention also provides a method for preparing the SAG1 protein mutant, comprising fermenting the host, collecting the fermentation supernatant, filtering it through a hollow fiber, and purifying it through an NI column and / or a ConA column to obtain the SAG1 protein mutant.

[0026] In some specific embodiments of the present invention, in the hollow fiber diafiltration, the volume multiples of the diafiltration buffer and the fermentation supernatant include 10 times.

[0027] The present invention also provides the use of any of the following items in the preparation of an IgM detection kit, an IgG detection kit or a Toxoplasma gondii vaccine:

[0028] (I), the SAG1 protein mutant; and / or

[0029] (II), the nucleic acid molecule; and / or

[0030] (III), the recombinant vector; and / or

[0031] (IV), the host; and / or

[0032] (V) The SAG1 protein mutant obtained by the preparation method.

[0033] In some specific embodiments of the present invention, the SAG1 protein mutant is labeled with horseradish peroxidase.

[0034] The present invention also provides a vaccine comprising any of the following:

[0035] (I), the SAG1 protein mutant; and / or

[0036] (II), the nucleic acid molecule; and / or

[0037] (III), the recombinant vector; and / or

[0038] (IV), the host; and / or

[0039] (V) The SAG1 protein mutant obtained by the preparation method.

[0040] The present invention also provides a kit, comprising any of the following items:

[0041] (I), the SAG1 protein mutant; and / or

[0042] (II), the nucleic acid molecule; and / or

[0043] (III), the recombinant vector; and / or

[0044] (IV), the host; and / or

[0045] (V) The SAG1 protein mutant obtained by the preparation method.

[0046] The present invention includes but is not limited to providing the following beneficial effects:

[0047] By targeted mutation of N-glycosylated amino acids, the expression of non-glycosylated SAG1 protein was increased from 28% to 100%. Without affecting the structure and function of SAG1, the production of SAG1 can be increased and the cost can be reduced. The SAG1 protein can also be secreted into the supernatant, reducing the difficulty of the purification and separation process and improving the yield. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0049] Figure 1 The diagram of pPIC9K plasmid used for yeast expression is shown;

[0050] Figure 2 The results of SAG1-Mut-pPIC9K yeast expression and NI column purification SDS-PAGE are shown, where SY is the hollow fiber filtrate and NI column purification loading, LC is NI flow-through; 2% is the 20mM imidazole dissociation sample, and 50% is the 500mM imidazole purification sample;

[0051] Figure 3 The results of SDS-PAGE of NI column purification of SAG1-pPIC9K yeast expression are shown, where ZY is the hollow fiber concentrated sample; SY is the NI column purification loading, LC is the NI flow-through; 2% B is the 20mM imidazole dissociation sample, and 50% B-1 and -2 are the samples after 500mM imidazole purification;

[0052] Figure 4The results of SDS-PAGE of the final product of SAG1-Mut-pPIC9K purified by ConA column are shown, wherein JL is the ConA dissociation sample; SY is the ConA loading sample, and LC is the final target protein harvested;

[0053] Figure 5 The results of SDS-PAGE purification of the final product of SAG1-pPIC9K by ConA chromatography column are shown, wherein SY is the ConA loading sample, LC-1 to LC-6 are the final target proteins harvested, and JL is the purified glycosylated protein;

[0054] Figure 6 The graph shows the SDS-PAGE results of sugar chains released by SAG1 glycosylation protease treatment, where glycosylation is the untreated SAG1 glycosylated protein, enzymes 1 to 4 are the results of different enzyme treatments, and non-glycosylation is the non-glycosylated target protein purified by SAG1 ConA. DETAILED DESCRIPTION

[0055] The present invention discloses a SAG1 protein mutant and a preparation method and application thereof. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve the desired results. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0056] The invention provides a yeast homogeneously expressed Toxoplasma gondii SAG1 recombinant protein, wherein the recombinant protein is fused with a HIS tag protein.

[0057] Since the proportion of glycosylated proteins in conventional expression is as high as 70% (SDS-PAGE analysis of NI purified protein), the present application chooses to mutate a glycosylation site without changing its structure and antigenic activity, and the non-glycosylated expression is about 100%, which increases the final antigen yield by more than 10 times.

[0058] The technical scheme of this invention is: construct yeast expression plasmid - electrotransform yeast - stable cell strain screening - fermentation expression - protein purification. The present invention utilizes the existing SAG1 antigen sequence in the laboratory, performs site-directed amino acid mutation, clones it into the yeast expression vector pPIC9K, electrotransforms it into Pichia pastoris and screens stable cell strains, adopts high-density fermentation culture technology, harvests the fermentation broth supernatant, performs hollow fiber filtration to remove the culture medium, and then performs NI column and ConA purification, thereby obtaining 100% pure protein.

[0059] Preferably, the SAG1 mutant sequence is shown in SEQ ID NO: 1.

[0060] SAG1 mutant amino acid sequence (SEQ ID NO: 1):

[0061] MSDPPLVANQVVTCPDKKSTAAVILTPTENHFTLKCPKTALTEPPTLAYSPNRQICPAGTTSSCTSKAVTLSSLIPEAEDSWWTGDSASLDTAGIKLTVPIEKFPVTTQTFVVGCIKGDDAQSCMVTVTVQAR ASSVVNNVARCSYGADSTLGPVKLSAEGPTTMTLVCGKDGVKVPQDNNQYCSGTTLTGCNEKSFKDILPKLTENPWQGQASSDKGATLTIKKEAFPAESKSVIIGCTGGSPEKHHCTVKLEFAGAAGSAKSA.

[0062] SAG1 mutant nucleotide sequence (SEQ ID NO: 2):

[0063] ATGTCGGATCCCCCTCTTGTTGCCAATCAAGTTGTCACCTGCCCAGATAAAAAATCGACAGCCGCGGTCATTCTCACACCGACGGAGAACCACTTCACTCTCAAGTGCCCTAAAACAGCGCTCACAGAGCCTCCCACTCTTGCGTACTCACCCAACAGGCAAATCTGCCCAGCGGGTACTACAAGTAGCTGTACATCAAAGGCTGTAACATTGAGCTCCTTGATTCCTGAAGCAGAAGATAGCTGGTGGACGGGGGATTCTGCTAGTCTCGACACGGCAGGCATCAAACTCACAGTTCCAATCGAGAAGTTCCCCGTGACAACGCAGACGTTTGTGGTCGGTTGCATCAAGGGAGACGACGCACAGAGTTGTATGGTCACAGTGACAGTACAAGCCAGAGCCTCATCGGTCGTCAATAATGTCGCAAGGTGCTCCTACGGTGCAGACAGCACTCTTGGTCCTGTCAAGTTGTCTGCGGAAGGACCCACTACAATGACCCTCGTGTGCGGGAAAGATGGAGTCAAAGTTCCTCAAGACAACAATCAGTACTGTTCCGGGACGACGCTGACTGGTTGCAACGAGAAATCGTTCAAAGATATTTTGCCAAAATTAACTGAGAACCCGTGGCAGGGTCAGGCTTCGAGTGATAAGGGTGCCACGCTAACGATCAAGAAGGAAGCATTTCCAGCCGAGTCAAAAAGCGTCATTATTGGATGCACAGGGGGATCGCCTGAGAAGCATCACTGTACCGTGAAACTGGAGTTTGCCGGGGCTGCAGGGTCAGCAAAATCGGCT

[0064] Amino acid sequence of SAG1 (SEQ ID NO: 3):

[0065] MSDPPLVANQVVTCPDKKSTAAVILTPTENHFTLKCPKTALTEPPTLAYSPNRQICPAGTTSSCTSKAVTLSSLIPEAEDSWWTGDSASLDTAGIKLTVPIEKFPVTTQTFVVGCIKGDDAQSCMVTVTVQARASSVVNNVARCSYGADSTLGPVKLSAEGPTTMTLVCGKDGVKVPQDNNQYCSGTTLTGCNEKSFKDILPKLTENPWQGNASSDKGATLTIKKEAFPAESKSVIIGCTGGSPEKHHCTVKLEFAGAAGSAKSA

[0066] Nucleotide sequence of SAG1 (SEQ ID NO: 4):

[0067] ATGTCGGATCCCCCTCTTGTTGCCAATCAAGTTGTCACCTGCCCAGATAAAAAATCGACAGCCGCGGTCATTCTCACACCGACGGAGAACCACTTCACTCTCAAGTGCCCTAAAACAGCGCTCACAGAGCCTCCCACTCTTGCGTACTCACCCAACAGGCAAATCTGCCCAGCGGGTACTACAAGTAGCTGTACATCA AAGGCTGTAACATTGAGCTCCTTGATTCCTGAAGCAGAAGATAGCTGGTGGACGGGGGATTCTGCTAGTCTCGACACGGCAGGCATCAAACTCACAGTTCCAATCGAGAAGTTCCCCGTGACAACGCAGACGTTTGTGGTCGGTTGCATCAAGGGAGACGACGCACAGAGTTGTATGGTCACAGTGACAGTACAAGCCA GAGCCTCATCGGTCGTCAATAATGTCGCAAGGTGCTCCTACGGTGCAGACAGCACTCTTGGTCCTGTCAAGTTGTCTGCGGAAGGACCCACTACAATGACCCTCGTGTGCGGGAAAGATGGAGTCAAAGTTCCTCAAGACAACAATCAGTACTGTTCCGGGACGACGCTGACTGGTTGCAACGAGAAATCGTTCAAAGA TATTTTGCCAAAATTAACTGAGAACCCGTGGCAGGGTAACGCTTCGAGTGATAAGGGTGCCACGCTAACGATCAAGAAGGAAGCATTTCCAGCCGAGTCAAAAAGCGTCATTATTGGATGCACAGGGGGATCGCCTGAGAAGCATCACTGTACCGTGAAACTGGAGTTTGCCGGGGCTGCAGGGTCAGCAAAATCGGCT

[0068] Preferably, a HIS tag is added to the C-terminus of the SAG1 mutant sequence to simplify the antigen purification process.

[0069] Preferably, the hollow fiber filtration multiple is verified by filtering out the reagent effectively.

[0070] As an optimization, the process adds ConA column purification. ConA will bind to glycoproteins in the conventional process. Glycosylation site mutation has been performed in this project, so the target protein expressed by the recombinant construct has no obvious glycosylation expression. However, in conventional yeast expression, some non-target glycoproteins will be secreted at the same time. Such proteins have no obvious characteristic bands on the electrophoresis diagram and are tailing bands. Conventional tag protein purification cannot effectively remove them. Therefore, this article uses ConA chromatography column to remove yeast supernatant to express other glycoproteins and increase the antigen purity to 100%.

[0071] By comparing the deglycosylation kit with the protein after sugar chain release, the SDS-PAGE analysis showed that the molecular weight of the protein was still larger than that of the non-glycosylated protein, indicating that the sugar chain release was not complete and failed to reach a completely sugar-free state.

[0072] The invention also provides a method for preparing the recombinant protein, comprising the following steps: constructing a yeast expression plasmid, electroporating yeast and screening stable cell lines, fermenting and culturing, and purifying the fermentation supernatant.

[0073] The invention also provides application of the recombinant protein in a Toxoplasma IgG detection kit and a Toxoplasma IgM detection kit.

[0074] The advantages of the present invention are:

[0075] By targeted mutation of N-glycosylated amino acids, the expression of non-glycosylated SAG1 protein was increased from 28% to 100%. Without affecting the structure and function of SAG1, the production of SAG1 can be increased and the cost can be reduced. The SAG1 protein can also be secreted into the supernatant, reducing the difficulty of the purification and separation process and improving the yield.

[0076] Unless otherwise specified, the SAG1 protein mutants provided by the present invention and the raw materials and reagents used in the preparation method and application thereof can all be purchased from the market.

[0077] The present invention will be further described below in conjunction with embodiments:

[0078] Example 1 Construction of recombinant strains

[0079] 1. Construction of plasmid containing target gene

[0080] (1) PCR amplification

[0081] According to the experimental requirements, the laboratory can select pPIC9K plasmid ( Figure 1 ) as a skeleton, the existing SAG1-pPIC9K template was subjected to directed amino acid mutation. According to the PCR system shown in Table 1 or Table 2, the PCR program shown in Table 3 was used for amplification to obtain the amplified DNA fragment.

[0082] Table 1 PCR system

[0083]

[0084] Table 2 PCR system

[0085]

[0086] Table 3 PCR program

[0087]

[0088] (2) Rubber recycling

[0089] The DNA fragment obtained in (1) was run on a 1% DNA agarose gel, and then recovered using a gel recovery kit from Omega (Cat. No. 2500-02) to obtain gel-recovered fragments, which were then subjected to bridge PCR.

[0090] (3) Bridging PCR

[0091] The primer information is shown in Table 4. After PCR, gel recovery (same as method (2)) was performed to obtain the target gene fragment, and then homologous recombination was performed: the target gene was digested and gel recovered to obtain the digestion recovery solution, and the digested vector was ligated to obtain the enzyme ligation solution.

[0092] Table 4 PCR system

[0093]

[0094] Table 5 Vectors and gene restriction enzyme digestion system

[0095] system volume 10*CUTSMARTbuffer 4μL EcoRI (10U / μL) 2μL NotI (10U / μL) 2μL Plasmid (concentration 800ng / μL) 2000ng <![CDATA[ddH2O]]> Up to 40 μL

[0096] The enzyme digestion was performed in a PCR instrument at 37°C for 2 h, and the DNA was recovered by running on a gel and then connected.

[0097] Table 6 Connection system

[0098] System size Other ligation reactions - 20 μl Target gene (concentration: 40ng / μL) 2μl Enzyme digestion of pPIC9K vector (concentration: 21ng / μL) 2μL Thermo10×T4 DNA Ligase Buffer 2μL ThermoT4 DNA ligase (5U / μL) 2μL <![CDATA[ddH2O]]> 12μL

[0099] The ligation was carried out at 16°C for 2 h, and the ligation product was taken out and placed in an ice bath for 10 min before transformation.

[0100] 2. Plasmid transformation

[0101] (1) Take the DH5α competent cells out of the refrigerator at ≤ -80°C and place them on ice to thaw. Take a 1.5 mL EP tube and place it on ice.

[0102] (2) Take 100 μL of competent cells and place them in a 1.5 mL EP tube. Add 10 μL of enzyme ligation solution, mix and place on ice for half an hour. The negative control is 0.5 μL of enzyme digestion recovery solution.

[0103] (3) Heat shock in a 42°C water bath for 90 seconds and ice bath for 2 minutes.

[0104] (4) Add 1 mL of antibiotic-free LB medium to the EP tube in a clean bench and incubate at 37°C, 220 rpm for 1 h.

[0105] (5) Centrifuge at 4000 rpm for 5 min at room temperature.

[0106] (6) Discard the supernatant in a clean bench, retain 100 μL of the supernatant, mix the bacteria and apply it to a plate (LB plate containing kanamycin).

[0107] (7) Place the cells in a 37°C incubator overnight. Monoclonal colonies will be visible after approximately 14 hours.

[0108] (8) Sequencing verification: After the sequence is correct, save the plasmid and express the cloned bacteria (the strain is DH5α).

[0109] 3. Plasmid linearization

[0110] Take the plasmid cloned with the correct sequence and perform linearization with SalI restriction enzyme digestion. The system is as follows:

[0111] Table 7 Plasmid linearization

[0112] system volume 10*CUTSMARTbuffer 4μL SalI (10U / μL) 4μL Plasmid (concentration 500ng / μL) 7000ng <![CDATA[ddH2O]]> Up to 40 μL

[0113] The enzyme digestion was performed in a PCR instrument at 37°C for 2 h. The digestion effect was identified by agarose gel and compared with the uncut plasmid. The linearized plasmid was recovered by Omega gel recovery kit and stored at ≤-20°C for future use.

[0114] 4. Electroporation of Pichia pastoris and screening of high expression strains

[0115] i) Preparation of competent cells and electroporation

[0116] (1) In a clean bench, streak a YPD plate with GS115 glycerol stock and incubate it upside down at 30°C for 3 days.

[0117] (2) In a clean bench, pick a single GS115 colony and place it in 3 mL of YPD liquid culture medium. Place it in a tabletop constant temperature oscillator and culture it overnight at 30°C and 230 rpm.

[0118] (3) In a clean bench, take 500 μL of overnight culture solution and inoculate 100 mL of YPD liquid medium. Place the culture medium in a tabletop constant temperature oscillator and culture it overnight at 30°C and 230 rpm.

[0119] (4) Transfer the overnight culture of GS115 to two 50 mL sterile centrifuge tubes, place on ice for 20 min, centrifuge at 4000 rpm at 4°C for 5 min, and discard the supernatant.

[0120] (5) Add 30 mL of pre-cooled high-pressure purified water to each tube and resuspend. Centrifuge at 4000 rpm for 5 min at 4°C and discard the supernatant.

[0121] (6) Add 30 mL of pre-cooled high-pressure purified water to each tube and resuspend. Centrifuge at 4000 rpm for 5 min at 4°C and discard the supernatant.

[0122] (7) Add 30 mL of pre-cooled 1 M sorbitol to resuspend the cells. Combine the two tubes of cells and centrifuge at 4000 rpm for 5 min at 4°C. Discard the supernatant.

[0123] (8) Add 100 μL-200 μL of pre-cooled 1 M sorbitol to resuspend.

[0124] (9) Pipette 100 μL of bacterial solution into an ice bath electroporation cup and shake the cup to allow the solution to settle to the bottom of the cup.

[0125] (10) Add 10 μL of linearized plasmid (3), mix gently, place on ice for 30 min, and set up a control experiment.

[0126] (11) Set the parameters of the electroporator for electric shock reaction:

[0127] V: 1.5kv C: 25uF R: 400Ω

[0128] (12) Immediately after electroporation, place the tube on ice and resuspend it in 1 mL of ice-cold 1 M sorbitol in a clean bench. Transfer the tube to a 1.5 mL centrifuge tube and incubate at 30 °C for 1–2 h.

[0129] (13) Resuspend the bacterial suspension, aspirate 100-200 μL and spread on MD plates, and incubate at 30°C for 3 days.

[0130] ii) Screening of high expression strains

[0131] The His+ clones grown on the MD plate were washed with 3 mL of YPD culture medium, spread evenly with a spreader stick, and the bacterial culture was aspirated into a 1.5 mL ep tube. The OD value was measured to be 3.7. 1 OD = 5 × 10 7 cells / mL,3.7OD=1.85×10 8 cells / mL, the general coating concentration is 10 5 / 200μL, so dilute 100 times. Take 200μL and spread on YPD-G418 plates with different concentration gradients (the concentration of G418 in YPD-G418 plates is: 0.25, 0.5, 2.0, 4.0, 8.0mg / mL). Culture at 30℃ for two days. Activate the high copy clones grown on G4184.0, 8.0mg / mL plates with MD medium, and identify the positive cases by PCR. The ones that are correctly identified are preserved.

[0132] iii) Preservation of high expression strains

[0133] Take 200 μL of the positively identified strain (expressing SAG1-Mut-pPIC9K) and inoculate it into 3 mL YPD liquid culture medium, culture it at 30°C overnight, and the next day, add 200 μL 80% glycerol + 800 μL bacterial solution and store it at ≤-80°C.

[0134] Example 2 Fermentation and initial purification

[0135] The yeast strain expressing SAG1-Mut-pPIC9K obtained in Example 1 was used for fermentation culture. First, BMGY medium was inoculated at a ratio of 1:100, placed in a desktop full-temperature oscillator, and cultured at 30°C and 230rpm for 15-16h to prepare primary seeds, and then BMGY medium was inoculated at a ratio of 1:20, and the secondary seeds were prepared under the same conditions.

[0136] A 20L fermentation tank was used for fermentation culture, with an initial fermentation volume of 10L. Secondary seeds were inoculated at a ratio of 1:20 for fermentation culture. Fermentation conditions were as follows: the pH of the fermentation liquid was controlled at 5.0, the temperature was 30°C, the ventilation volume was 1vvm, the tank pressure was 0.05MP, and the fermentation culture was carried out until the nutrients were exhausted and the dissolved oxygen jumped (about 20h). Then, 50% glycerol (800ml) was added, and the dissolved oxygen was maintained at 20%-40%. The addition was continued until the glycerol was exhausted and the dissolved oxygen jumped (about 8h). Then, methanol was added to induce expression, and the dissolved oxygen was maintained at 20%-40%. The induction process lasted for about 120h. After the fermentation was completed, about 12L of the fermentation liquid was collected by high-speed centrifuge.

[0137] Purification process: After the collected fermentation broth is concentrated 10-20 times using a hollow fiber, it is diafiltered using 0.02M TB pH8.5 buffer with a volume of 5-10 times the concentrate, and filtered using a 0.45μm filter membrane. Ultrapure water and 0.02M TB pH8.5 are used to balance a 200ml NI chromatography column, and then the filtered sample is loaded for NI column purification. After loading, the column is equilibrated with a buffer of 0.02M TB pH8.5 for a second time, and then 2% imidazole is used to wash the impurities and 50% imidazole is used to dissociate the target protein to obtain the sample purified by the NI column.

[0138] Example 3 Fine purification

[0139] The sample purified by NI column in Example 2 was subjected to ConA to remove glycoprotein. The operation steps were as follows: the NI purified sample was dialyzed into 0.02M PBS pH 7.4 at 1:50 for 3 times and filtered through 0.45 μm filter membrane for later use.

[0140] After equilibrating the ConA chromatography column with ultrapure water and 0.02M PBS pH7.4, load the filtered sample, collect the target protein and unglycosylated SAG1-Mut protein that flow through according to the protein UV peak, and stop collecting after the UV peak drops steadily. Use 0.02M PBS + 0.4M mannoside pH7.4 to dissociate the glycosylated protein.

[0141] Effect Example 1 Fermentation Culture Purification

[0142] Experimental groups:

[0143] Control group: The SAG1-pPIC9K plasmid was transformed into Pichia pastoris using the experimental method described in Example 1 to construct a yeast strain expressing SAG1-pPIC9K, and fermented and cultured using the method described in Example 2.

[0144] Experimental group: The yeast strain expressing SAG1-Mut-pPIC9K constructed in Example 1 was used and fermented using the method described in Example 2.

[0145] The results show that 1: In order to verify the hollow fiber filtration multiple, a biochemical analyzer was used to detect the replacement of each ion in the reagent to ensure that the buffer solution was fully replaced. The test results are as follows:

[0146] Table 8 Comparison of ion content in hollow fiber diafiltration buffer

[0147]

[0148] From the above results, the sample was concentrated to 1L and then diafiltered by 10 times the volume to replace the buffer. From the results, it can be seen that the buffer has been fully replaced after 10 times of diafiltration, and the components that affect NI binding during the yeast culture process have been fully replaced, and subsequent NI purification can be carried out.

[0149] The results show 2:

[0150] The same fermentation sample was purified by NI and then electrophoresed as shown in the figure: Figure 2 :SAG1-Mut-pPIC9K electrophoresis, after NI purification, the SAG1 protein was uniformly expressed with a purity of 92.3%; the control group electrophoresis Figure 3 As a result, the electrophoresis diagram of SAG1-pPIC9K NI purification showed that the non-glycosylation ratio of SAG1 after NI purification was 28.3%, which indicated that it was difficult to separate and purify a homogenized non-glycosylated protein.

[0151] After purification, the expression level of the NI column purified protein is shown in the following table: the total protein expression level in the supernatant of NI cells after mutation was slightly lower than that of the control group, but because the proportion of its expression of homogenized non-glycosylated protein was 92.3%, the final expression level of the target protein in the cell supernatant was much higher than that of the control group.

[0152] Table 9 Expression verification

[0153]

[0154] Effect Example 2 Fine Purification

[0155] Experimental groups:

[0156] Control group: The SAG1-pPIC9K plasmid was transformed into Pichia pastoris using the experimental method described in Example 1 to construct a yeast strain expressing SAG1-pPIC9K, which was fermented and cultured using the method described in Example 2, and ConA glycoprotein was removed using the method described in Example 3.

[0157] Experimental group: The yeast strain expressing SAG1-Mut-pPIC9K constructed in Example 1 was used for fermentation culture using the method described in Example 2, and the method described in Example 3 was used for ConA glycoprotein removal.

[0158] The results showed that the experimental group SAG1-Mut-pPIC9K had less impurities and that one-tenth of the sample volume of filler was sufficient to remove impurities. The purification results were as follows: Figure 4 As shown in the figure, the purity of SDS-PAGE analysis reached 100%; the control group SAG1-pPIC9K needs to be purified using a filler with the same volume as the sample volume. Due to the limited adsorption capacity of the filler, it is difficult to remove the remaining trace protein in the sample, and multiple repeated loading is required. The purification results are shown in the figure. Figure 5 The sample flowing through the ConA column was combined to form the target protein, and the purity of the sample was analyzed by SDS-PAGE to reach 95%.

[0159] Effect Example 3: Verification of Glycoprotein Sugar Chain Release

[0160] The bound glycoproteins were collected by SAG1-pPIC9K ConA purification, and then the sugar chains were released using a commercial kit. The specific information is shown in the following table:

[0161] Table 10 Sugar Chain Release Kit Information

[0162]

[0163]

[0164] The results of sugar chain release of purified and collected glycoprotein samples are as follows Figure 6 As shown in the figure, the target protein obtained after the sugar chain release of SAG1 glycoprotein has a larger molecular weight than the non-sugar expressed protein, indicating that the sugar chain release is not sufficient and some sugar chains still remain, and the residual sugar chains may still affect the performance of the kit.

[0165] Effect Example 4: The SAG1-Mut protein of this application is used as a coating antigen

[0166] The mutated SAG1-Mut protein prepared in Example 3 was used as the coating antigen for verification on the Antu TOX-IgG detection kit, and the titer was consistent with the control, and the clinical and specificity met the control requirements.

[0167] Table 11 Fusion protein expression

[0168] Antigenic properties Antigen coating titer Control group Prokaryotic recombinant chimeric protein (P30+P22+P35) 0.43 μg / mL Experimental Group Eukaryotic recombinant protein (SAG1-Mut) 0.5 μg / mL

[0169] Example 5 The SAG1-Mut protein of the present application is used as a marker antigen

[0170] The mutated SAG1-Mut protein prepared in Example 3 was labeled with HRP using the sodium periodate method and used as a labeled antigen for verification on the Antu TOX-IgM detection kit. The titer was consistent with the control, and the clinical and specificity met the control requirements.

[0171] Table 12 HRP-SAG1-Mut detection comparison

[0172]

[0173]

[0174] It can be seen that after SAG1-Mut labeled with HRP after site mutation, its applicability can still meet the product performance requirements.

[0175] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of N212Q site mutation in increasing the expression level of non-glycosylated SAG1 protein in yeast.

2. SAG1 protein mutants, It is characterized in that Including N212Q site mutation.

3. A nucleic acid molecule encoding the SAG1 protein mutant according to claim 2.

4. Recombinant vector, It is characterized in that Comprising the nucleic acid molecule as described in claim 3.

5. Host, It is characterized in that Comprising the recombinant vector as described in claim 4.

6. Use of any of the following in the preparation of SAG1 protein mutants: (I), a nucleic acid molecule as described in claim 3; and / or (II), the recombinant vector according to claim 4; and / or (III) The host according to claim 5.

7. The method for preparing the SAG1 protein mutant according to claim 2, It is characterized in that The method comprises fermenting the host as claimed in claim 5, collecting the fermentation supernatant, filtering it through a hollow fiber, and purifying it through an NI column and / or a ConA column to obtain the SAG1 protein mutant.

8. Use of any of the following in the preparation of IgM detection kits, IgG detection kits or Toxoplasma gondii vaccines: (I) the SAG1 protein mutant according to claim 2; and / or (II), the nucleic acid molecule according to claim 3; and / or (III), the recombinant vector according to claim 4; and / or (IV), the host according to claim 5; and / or (V) A SAG1 protein mutant obtained by the preparation method according to claim 7.

9. Vaccines, It is characterized in that Include any of the following: (I) the SAG1 protein mutant according to claim 2; and / or (II), the nucleic acid molecule according to claim 3; and / or (III), the recombinant vector according to claim 4; and / or (IV), the host according to claim 5; and / or (V) A SAG1 protein mutant obtained by the preparation method according to claim 7.

10. Test kit, It is characterized in that Include any of the following: (I) the SAG1 protein mutant according to claim 2; and / or (II), the nucleic acid molecule according to claim 3; and / or (III), the recombinant vector according to claim 4; and / or (IV), the host according to claim 5; and / or (V) A SAG1 protein mutant obtained by the preparation method according to claim 7.